All In Biotech

Drug Trial Radar · NCT01674140

S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer

Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,939 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,939

Actual

Start

Sep 12, 2013

Primary completion

Dec 1, 2022

Study completion Jan 2030

Sponsor

Lead sponsor
SWOG Cancer Research NetworkResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI)
First posted
Aug 28, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate, goserelin acetate, leuprolide acetate, anastrozole, letrozole, or exemestane, may fight breast cancer by lowering the amount of estrogen the body makes. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet know whether hormone therapy is more effective when given with or without everolimus in treating breast cancer. PURPOSE: This randomized phase III trial studies how well giving hormone therapy together with or without everolimus work in treating patients with breast cancer.

Conditions

  • Breast Cancer

Interventions

  • anastrozoleDrug

    Given orally

  • everolimusDrug

    Given PO

  • exemestaneDrug

    Given orally

  • goserelin acetateDrug

    Given subcutaneously or intramuscularly

  • letrozoleDrug

    Given orally

  • leuprolide acetateDrug

    Given subcutaneously or intramuscularly

  • tamoxifen citrateDrug

    Given PO

  • placeboOther

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Invasive Disease-Free Survival (IDFS)Time frame: Up to 5 years post registration

Locations

1,458 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama

  • Anchorage Associates in Radiation Medicine

    Anchorage, Alaska

  • Anchorage Radiation Therapy Center

    Anchorage, Alaska

  • Alaska Breast Care and Surgery LLC

    Anchorage, Alaska

  • Alaska Oncology and Hematology LLC

    Anchorage, Alaska

  • Alaska Regional Hospital

    Anchorage, Alaska

  • Alaska Women's Cancer Care

    Anchorage, Alaska

  • Anchorage Oncology Centre

    Anchorage, Alaska

  • Katmai Oncology Group

    Anchorage, Alaska

  • Providence Alaska Medical Center

    Anchorage, Alaska

  • Fairbanks Memorial Hospital

    Fairbanks, Alaska

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona

  • University of Arizona Cancer Center at Saint Joseph's

    Phoenix, Arizona

  • University of Arizona Cancer Center-Orange Grove Campus

    Tucson, Arizona

  • University of Arizona Cancer Center-North Campus

    Tucson, Arizona

  • The University of Arizona Medical Center-University Campus

    Tucson, Arizona

  • Yuma Cancer Center

    Yuma, Arizona

  • CHI Saint Vincent Cancer Center Hot Springs

    Hot Springs, Arkansas

  • Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro

    Jonesboro, Arkansas

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • Highlands Oncology Group-Rogers

    Rogers, Arkansas

  • Kaiser Permanente-Anaheim

    Anaheim, California

  • Kaiser Permanente-Deer Valley Medical Center

    Antioch, California

  • PCR Oncology

    Arroyo Grande, California

  • Sutter Auburn Faith Hospital

    Auburn, California

  • Sutter Cancer Centers Radiation Oncology Services-Auburn

    Auburn, California

  • AIS Cancer Center at San Joaquin Community Hospital

    Bakersfield, California

  • Kaiser Permanente-Baldwin Park

    Baldwin Park, California

  • Kaiser Permanente-Bellflower

    Bellflower, California

  • Alta Bates Summit Medical Center-Herrick Campus

    Berkeley, California

  • Providence Saint Joseph Medical Center/Disney Family Cancer Center

    Burbank, California

  • Mills-Peninsula Medical Center

    Burlingame, California

  • Sutter Cancer Centers Radiation Oncology Services-Cameron Park

    Cameron Park, California

  • Mercy San Juan Medical Center

    Carmichael, California

  • East Bay Radiation Oncology Center

    Castro Valley, California

  • Eden Hospital Medical Center

    Castro Valley, California

  • Valley Medical Oncology Consultants-Castro Valley

    Castro Valley, California

  • John Muir Medical Center-Concord Campus

    Concord, California

  • City of Hope Corona

    Corona, California

  • UC Irvine Health Cancer Center-Newport

    Costa Mesa, California

Showing 40 of 1,458 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.